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Lysosomal disorders are diseases that involve mutations in genes responsible
for the coding of lysosomal enzymes, transport proteins, activator proteins
and protein processing enzymes. These defects lead to the storage of specific
metabolites within lysosomes resulting in a great variety of clinical features
depending on the tissues with the storage, the storage products and the
extent of the storage. The methods for rapidly diagnosing patients started in
the late 1960's when the enzyme defects were identified eliminating the need
for tissue biopsies. The first requests for diagnostic help in this laboratory
came in 1973. In that year, patients with Krabbe disease and Niemann-Pick
type A were diagnosed. Since that time samples from about 62 000 individ-
uals have been received for diagnostic studies, and 4900 diagnoses have been
made. The largest number of diagnosed individuals had metachromatic leu-
kodystrophy and Krabbe disease because of our research interest in leuko-
dystrophies. A number of new disorders were identified and the primary
defects in other disorders were clarified. With new methods for diagnosis,
including newborn screening, molecular analysis, microarrays, there is still
a need for biochemical confirmation before treatment is considered. With new
treatments, including gene therapy, stem cell transplantation, enzyme replace-
ment used alone or in combination becoming more available, the need for rapid,
accurate diagnosis is critical.
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In this manuscript we review the history of the Lyso-
somal Diseases Testing Laboratory (LDTL) from the ini-
tial requests for testing in 1973 to the present. In addition
to providing information on the number of patients with
each disorder diagnosed, we will highlight some of the
more interesting cases that opened new thinking about
this group of genetic disorders. In 1971, David A. Wenger
was offered a position as an Assistant Professor of Pediat-
rics at the University of Colorado Medical Center. There
was some initial funding from the B. F. Stolinsky family
because of a niece with Gaucher disease. The only stipu-
lation was for him to do research on lysosomal disorders.
He was recruited from the laboratory of Dr. John
S. O'Brien, who first identified the deficiency of
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hexosaminidase A activity in patients with Tay-Sachs dis-
ease, where he was a postdoctoral fellow. About that time
the biochemical defects were being identified opening the
way to rapid and simpler diagnostic tests which elimi-
nated the need for brain or other organ biopsies. The
measurement of enzymes activities in blood samples or
cultured skin fibroblasts became the standard for diag-
nostic testing. Another advancement that improved the
sensitivity of the diagnostic testing was the increasing
commercial availability of fluorogenic substrates
replacing colorimetric and natural substrates. At that
time, the genes for the lysosomal enzymes and proteins
had not been cloned but that would begin within the next
15 years opening additional options for diagnosis, for
genotype-phenotype correlations and eventually for
treatment.
Initial research projects in the laboratory included stud-
ies on Krabbe disease, Niemann-Pick types A, B, and C,
and Gaucher disease. Mainly these studies involved exami-
nation of autopsy tissues from patients who died with these
disorders to look for biochemical changes that could lead
to a better understanding of the pathogenesis of the dis-
eases. In 1970, Malone1 and Suzuki and Suzuki2 found that
patients with Krabbe disease were deficient in the beta-
galactosidase activity that catalyzed the hydrolysis of galac-
tose from galactosylceramide, a key sphingolipid in myelin.
Patients with GM1 gangliosidosis were deficient in another
beta-galactosidase that catalyzed the hydrolysis of the ter-
minal galactose from GM1 ganglioside, GA1, keratan sul-
fate as well as glycoproteins, but not galactosylceramide.
In 1973 a child neurologist in the Department of Pedi-
atrics saw a 3-month-old child who was developmentally
delayed, extremely irritable, and stiff. She suspected a dis-
order like Krabbe disease or Tay-Sachs disease and asked
if the laboratory could help make a diagnosis. The assays
for these enzymes were already in use, but had not been
used for diagnostic studies. Blood was taken from labora-
tory personnel and the patient, and leukocytes were iso-
lated using dextran according to a published procedure.3
The results showed near zero galactocerebrosidase
(GALC) activity and normal activity for other lysosomal
enzymes confirming the diagnosis of Krabbe disease. The
same year there was a request for testing of a 6-month-
old child with developmental delay, an enlarged liver,
and bilateral macular cherry-red spots. Very low acid
sphingomyelinase activity was measured, and a diagnosis
of Niemann-Pick type A was made. In 1973, the labora-
tory had less than ten requests for diagnostic help. Addi-
tional request for testing started to come from centers
outside of Colorado. After determining that enzymes
could be measured in isolated leukocytes and plasma
from unclotted blood received 1 or 2 days after collection,
word went out that the laboratory would be able to help
with diagnostic testing in patients from around the coun-
try. The selection of tests to be assayed on each patient is
based on suggestions from the sending physician and our
suggestions from the clinical information supplied with
the sample. These diseases are not common and many
physicians may only see one or two patients during their
entire medical career. By receiving clinical information
with each sample, we could identify some key findings
that might suggest testing that would not be obvious to
the physician (Table 1). The increase in samples received
continued even when LDTL moved from Denver to Jef-
ferson Medical College in Philadelphia in 1986.
At this time samples from about 62 000 individuals
have been received by this laboratory for testing. This has
resulted in about 4900 definitive diagnoses (a “hit” rate of
about 8%; Table 2). It should be understood that this lab-
oratory never tested for all of the lysosomal disorders.
Some of the mucopolysaccharidoses (MPS), including
MPS II, MPS III A, C, and D, MPS IVA and other diseases
were never tested for and testing was stopped for other
disorders due to a lack of requests (eg, Farber disease).
Testing for some disorders, like Pompe disease and
Niemann-Pick type C, came later. A decision was made
to not charge by the test but to charge a flat rate for all
tests performed. This allowed us to perform all tests indi-
cated by the information provided to try to arrive at a
diagnosis, even if the probability of a diagnosis was slim.
This philosophy also resulted in some unexpected diag-
noses on patients with atypical presentations. That is the
advantage of having clinical information on thousands of
samples received here. Not all tests available in the labo-
ratory are run on every individual, however, we are lib-
eral in our test selection knowing that not all patients
have a “classical” presentation. We feel it is not necessary
to test for certain disorders if certain key features are not
mentioned.
Looking at Table 2 it may be surprising that the dis-
eases with the highest number of diagnoses are meta-
chromatic leukodystrophy (MLD) and Krabbe disease.
However, this reflects a number of factors including the
research interests of the laboratory in leukodystrophies
and the availability of radiolabeled galactosylceramide
for the diagnosis of Krabbe disease. In addition, the com-
mercial availability of synthetic substrates increased the
number of laboratories that can perform the tests for
SYNOPSIS
After 47 years the laboratory has diagnosed 4900
patients with a lysosomal storage disease and has
characterized some new diseases.
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certain lysosomal disorders. It is assumed a larger num-
ber of patients would be diagnosed with Gaucher disease
and MPS I as was found in Brazil by Giugliani et al.4
Samples come to the LDTL from all over the United
States which now has a very diverse population com-
pared to 35 to 45 years ago when samples tended to come
more from a northern European population (based on
the surnames of the individuals). From the data on the
Table 2 and the reasons provided, it is not possible to
assign a frequency for each of these diseases.
All lysosomal disorders include patients with a wide
range of ages of onset and clinical course, but for the pur-
pose of this publication this was not taken into account.
The number of diagnosed patients with the same disease
designation are listed together. Patients with mutations
in the same gene can have a very different clinical pic-
ture. For example, patients with GM1 gangliosidosis and
MPS IVB have mutations in the acid beta-galactosidase
gene. Different mutations can change the enzyme's abil-
ity to hydrolyze the terminal beta-linked galactose moiety
from different substrates resulting in different storage
products in different organs. In 1970, Dawson and Stein5
described a patient with a neurovisceral disease, evidence
for storage of lactosylceramide and other lipids in liver
and low lactosylceramide beta-galactosidase activity. It
was called lactosylceramidosis. Studies using different
assay conditions did not show a defect in hydrolyzing the
beta-linked galactose from lactosylceramide,6 and addi-
tional studies by this laboratory showed that the patient
had Niemann-Pick type C.
TABLE 1 Key features that determine which tests are
performed
1. Developmental delay and/or regression of previous learned
skills, ataxia, spasticity, hypotonia, behavioral changes, white
matter changes on MRI, seizure, and muscle weakness
(without presence of coarse facial features, short stature,
organomegaly, etc.)
– GM1 and GM2 gangliosidoses, metachromatic
leukodystrophy, Krabbe disease, β-mannosidosis,
α-fucosidosis, Pompe disease.
2. Coarse facial features, dysostosis multiplex or short stature
with or without developmental delay, organomegaly, eye
changes etc.
– GM1 and GM2 gangliosidoses, MPS I, IIIB, VI and VII,
α-fucosidosis, α and β-mannosidosis, ML II and III,
sialidosis, galactosialidosis, sialuria, sialic acid storage
disease, and multiple sulfatase deficiency.
3. Organomegaly with or without developmental delay
– Gaucher disease, Niemann-Pick types A, B and C, Wolman
disease, cholesteryl ester storage disease.
4. Eye findings
(A) Macular cherry-red spots
– GM1 and GM2 gangliosidoses, Niemann-Pick types A,
B and C, sialidosis, galactosialidosis, Krabbe disease.
(B) Corneal clouding
– GM1 gangliosidosis, MPS I, VI and VII, α-fucosidosis,
α-mannosidosis, β-mannosidosis, ML II and III,
sialidosis, galactosialidosis, Fabry disease, and
multiple sulfatase deficiency.
(C) Miscellaneous eye finding
– Tortuosity of conjunctival vessels (Fabry disease,
α-fucosidosis)




– Fabry disease, α-fucosidosis, GM1 gangliosidosis,
sialidosis, galactosialidosis, β-mannosidosis.
(B) Nonimmune fetal hydrops
– GM1 gangliosidosis, Gaucher disease, Niemann-Pick
types A, MPS VII, Sialidosis, galactosialidosis, sialic
acid storage disease, MPS I, ML II.
(C) Light pigmented skin
– Sialic acid storage disease
TABLE 2 Number of patients diagnosed in the Lysosomal







Mucolipidosis II and III 246






Krabbe disease 771 Fucosidosis 49




Fabry disease 124 Sialidosis, Sialuria, SASDc 82
Wolman & CESDd 50 Galactosialidosis 40
MPS I (H, HS, Se) 479 Multiple sulfatase deficiency
27
MPS VI 86 Farber disease 8
Pompe disease 16
Note: Total = 4896.
aIncludes Tay-Sachs disease, Sandhoff disease, and GM2 activator protein
deficiency.
bIncludes Niemann-Pick type A, B, and C.
cSialic acid storage disease.
dCholesterol ester storage disease.
eIncludes Hurler, Hurler-Scheie, and Scheie syndromes.
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In addition, there are patients who are phenotypically
very similar and share the same pathological features but
have mutations in different genes. This is true for the
450 patients diagnosed with GM2 gangliosidosis. Some of
these patients have Tay-Sachs disease (deficiency of
hexosaminidase A, Hex A), some have Sandhoff disease
(deficiency of hexosaminidases A and B, Hex A and B)
and some have normal measured hexosaminidase activity
(deficiency of GM2 activator protein). The differential
diagnosis of GM2 gangliosidoses can be simple but
requires the ability to separately measure Hex A and Hex
B activities using differences in heat stabilities of Hex A
and B and by using a sulfated synthetic substrate that
almost exclusively measures Hex A activity.7 There are
patients with GM2 gangliosidosis who have mutations in
the α-chain of Hex A that will only be diagnosed using
the sulfated substrate and could be missed using the heat
denaturation method. It is called the B1 variant of GM2
gangliosidosis. When we first published on such a patient
in 1983 we called the disease GM2 gangliosidosis Hex
AmB variant to indicate that the α-chain of Hex A has a
mutation missed by the heat denaturation method.8
Patients who clinically resemble GM2 gangliosidosis but
who have normal Hex A and B activity may have a defi-
ciency of GM2 activator protein required for bringing
GM2 ganglioside together with Hex A. The diagnosis was
made in six patients by looking at the increase in GM2
ganglioside in cerebrospinal fluid using a method devel-
oped in this laboratory.9
The laboratory also made some discoveries related to
the recognition of new lysosomal diseases and the clarifi-
cation of the cause of previously described disorders. By
1980, several articles were published describing patients
with low acid beta-galactosidase activity but varying clini-
cal presentations.10-13 Also, Hans Galjaard and coworkers
reported that when cultured cells from certain patients
with “GM1 gangliosidosis” were grown together and
chemically fused there was an increase in acid beta-
galactosidase activity showing genetic complementation.14
This laboratory had diagnosed a juvenile patient with low
(about 10% of normal) beta-galactosidase activity in leuko-
cytes and cultured skin fibroblasts. The mother did not
have carrier levels of beta-galactosidase activity. Seeing
clinical features similar to patients with sialidase defi-
ciency, the activity of sialidase was measured in the cul-
tured fibroblasts of the patient, and very low activity was
measured.15 Therefore this patient had a combined defi-
ciency of beta-galactosidase and sialidase activities. It came
to be called galactosialidosis. Alessandra d'Azzo and col-
leagues discovered that patients with galactosialidosis had
reduced levels of a “protective protein,” later found to be
cathepsin A needed for lysosomal localization and activa-
tion of both acid beta-galactosidase and sialidase.16
In 1981, Jones and coworkers described a goat with
very low β-mannosidase activity.17 This enzyme is needed
for the lysosomal hydrolysis of β-linked mannose resi-
dues found primarily in glycoproteins. At that time no
human patients with β-mannosidase deficiency had been
described. Therefore, the laboratory developed an assay
for β-mannosidase activity and tested every sample for
this enzyme along with other lysosomal enzymes. Within
6 months of starting to test for this enzyme a patient with
very low β-mannosidase activity in leukocytes and
plasma was identified.18 He excreted the expected prod-
uct, mannose-β-N-acetyglucosamine, in his urine. The
unrelated parents had about half normal β-mannosidase
activity as expected for carriers of an autosomal recessive
disease. However, additional testing of the urine showed
that he was also excreting excess glycosaminoglycans,
mainly heparan sulfate. Further testing showed that he
was also deficient in heparan N-sulfatase activity as
found in patients with Sanfilippo type A (MPS IIIA). This
is not the only time a patient was found to have two dif-
ferent lysosomal disorders. However, it is extremely
unusual for this to happen with such a very rare disease
such as β-mannosidosis, where only five additional
patients have been diagnosed in the LDTL since 1986.
The gene for arylsulfatase A (ARSA) was cloned in
1990,19 and since then over 200 mutations (hgmd.cf.ac.
uk) have been identified in patients with MLD. While
this disease is pan-ethnic, this laboratory diagnosed a
number of late infantile patients in the Navajo Indian
and Yupik Eskimo populations. An MD-PhD student in
the laboratory, Nuria Pastor-Soler, initially found the
mutation causing MLD in Navajo children. This muta-
tion was homozygous in all the affected children and het-
erozygous in the parents.20 She then looked for the
mutation in the Eskimo children, not expecting it to be
the same one found in the Navajos. However, they have
the same mutation as the Navajo that has never been
found in any other population in the world.21 Our studies
show that the Navajo and Yupik Eskimo populations
interacted exchanging genetic information.
Diagnosing patients with Gaucher disease became
more important after the development of enzyme
replacement therapy in 1990.22 This is a disease with a
wide age range of patients from newborns to the elderly.
The clinical features in non-neuronopathic Gaucher dis-
ease (type 1), even in siblings with the same genotype,
can be quite variable. Many years can separate the onset
of clinical features. However, in almost all cases, if one
sibling has the non-neuronopathic form, the other sib-
lings will also, and conversely the same is true of the
acute neuronopathic form (type 2). However, in one fam-
ily we identified two siblings who died at eight months
and one year with type 2 Gaucher disease and a 25-year-
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old full sibling who was mildly affected with type
1 Gaucher disease.23 At that time the mother and father
were clinically normal. Enzymatic testing showed that
the father had a carrier level of glucocerebrosidase activ-
ity, and the mother had glucocerebrosidase activity in the
affected range for Gaucher disease. Later studies showed
that the father carried a severe mutation (L444P) and the
mother was a compound heterozygote with a severe
(L444P) and a mild mutation (N370S). The two children
with acute neuronopathic Gaucher disease inherited two
copies of the severe mutation and the mildly affected son
inherited the father's severe mutation and the mother's
mild mutation. The mother was later found to have mod-
erate splenomegaly. The son and his mother have an
identical genotype (N370S/L444P) with considerable vari-
ability in clinical presentation.24
The methods used for biochemical testing in this lab-
oratory have not changed much in 47 years.25 However,
once the genes for the lysosomal proteins were cloned,
methods for detecting mutations were developed. Rapid
methods for isolating DNA from very small tissue sam-
ples, even dried blood spots (DBS), and development of
polymerase chain reaction have changed the options
available for testing patients. Also, the price for
mutation-based testing has dropped dramatically in the
last five years. However, the identification of one or two
mutations in a gene does not automatically make the
diagnosis in an individual. Many “mutation positive”
cases require follow-up testing using biochemical
methods to confirm that what was found molecularly is
actually disease causing. Also, it is essential to obtain a
diagnosis as quickly as possible before significant patho-
logical changes occur especially in the nervous systems.
This has resulted in newborn screening (NBS) for a num-
ber of lysosomal disorders.26,27 The diseases tested for
and methods used vary from state to state, however most
rely on enzymatic testing using DBS and tandem mass
spectroscopy. While these methods are rapid and specific,
they are screening tests, not diagnostic tests. Samples
from infants who test positive in a NBS test arrive in this
laboratory for confirmatory testing. Most of these screen-
positive infants will have additional testing including
measurement of biomarkers, mutation analysis, and
neurodiagnostic studies. As some treatments are expen-
sive and not without risks, the diagnosis must be
conclusive.
Another function of the LDTL is to measure the activ-
ity of enzymes in cord blood samples that will be used for
hematopoietic stem cell transplantation. Also, once the
transplantation has taken place the treated patients are
followed closely for years, and blood samples are sent to
the LDTL to measure the enzymatic activity to confirm
that activity from the donor cells is still being
maintained. Samples still arrive in the laboratory from
individuals transplanted more than 20 years ago.
In addition to the patient testing by the LDTL there is
also a research arm that has resulted in the cloning of
several genes that are currently being used for diagnostic
purposes and gene therapy. Studies on patients with fea-
tures suggestive of MLD, but with normal arylsulfatase A
activity resulted in the confirmation that these patients
were deficient in a specific sphingolipid activator protein
required for the enzymatic hydrolysis of sulfatide.28 The
antibodies produced in this laboratory were used to show
the deficiency of this activator protein in cultured cells
from the patients and to clone the activator protein gene,
now called prosaposin.29,30 That lead to the identification
of mutations in the prosaposin gene.31,32
The earliest research efforts were to purify GALC, the
enzyme deficient in patients with Krabbe disease. After
nearly 20 years of research the GALC protein was purified,33
and amino acid sequence information lead to the cloning of
the cDNA and gene.34,35 Over 250 disease-causing mutations
in the GALC gene have now been identified (hgmd.cf.ac.
uk), and this information is helpful in predicting the type of
Krabbe disease an individual could have when identified in
a NBS test.27 Also, published studies show that injection of
GALC cDNA in an AAV viral vector into animal models of
Krabbe disease along with bone marrow transplantation can
correct the pathology of the disease and greatly extend the
lives of treated animals.36 This treatment is moving toward a
clinical trial in human patients. Therefore, the LDTL has
served a useful function for 47 years and continues to pro-
vide information critical to the diagnosis and treatment of
lysosomal disorders.
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